Moneycontrol
you are here: HomeNewsEconomyPolicy
Oct 13, 2017 06:49 PM IST | Source: Moneycontrol.com

MSF moves High Court against Indian patent given to Pfizer's pneumonia vaccine

In its petition MSF argued that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious.

ByViswanath Pilla
MSF moves High Court against Indian patent given to Pfizer's pneumonia vaccine

Moneycontrol News

Médecins Sans Frontières (MSF) or Doctors Without Borders - the Paris-based international humanitarian-aid organization on Friday, said it has filed a petition in the High Court of Delhi to overturn the patent granted by Indian Patent Office to the US-based Pfizer’s pneumococcal conjugate vaccine (PCV).

In its petition MSF argued that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious.

MSF argued that the mere addition of serotypes to the already established 7-valent vaccine did not involve a technical advancement – it was merely a tactic to preserve Pfizer’s monopoly for many more years.

“Examiners in the Indian Patent Office must be aware that the decision they take to grant a patent can directly affect access to life-saving medicines and vaccines in India and across the developing world,” said Leena Menghaney, the petitioner who is representing the medical aid organization in court.

“MSF is appealing to the court to annul the decision to grant the patent and the patent office to hear the matter afresh,” Menghaney said.

Earlier this year, on August 13, the Indian Patent Office granted a patent to Pfizer for its PCV 13 product, marketed as Prevnar13, which will expire only in 2026.

MSF had challenged Pfizer’s unmerited patent claims on the vaccine in India last year to enable and accelerate the availability of more affordable versions of PCV. MSF also urged Indian government to issue compulsory license to Indian manufacturers to produce the vaccine.

“While MSF has initiated the legal process to challenge the patent, the actual revocation of an unmerited patent takes years. Looking at the urgent need for this vaccine, we really hope that the Indian Health Ministry in the meantime consider issuing a government use licence, to encourage manufacturers who have been developing more affordable PCV13 vaccines to continue with phase 3 clinical trials and deliver the life-saving vaccine for the immunization programme, not just in India but across the world,” said Yuanqiong Hu, Legal & Policy Advisor, MSF Access Campaign.

Globally, pneumonia causes more than a quarter of deaths in children under the age of five – nearly one million young lives lost per year. India carries the world’s highest burden of pneumonia, accounting for nearly 20 percent of these global infant pneumonia deaths.

The PCV13, which safeguards against 13 types of pneumococcal bacteria, also lowers the likelihood of antimicrobial resistance (AMR) by significantly reducing common childhood infections and decreasing the need for antibiotic use among infants and children.

“Millions of babies and young kids around the world are left unprotected against pneumonia as many governments cannot afford the high price of PCV set by pharmaceutical corporations,” said Dr. Greg Elder, Medical Coordinator, MSF Access Campaign. “As doctors who have watched far too many children die of pneumonia, we’re not going to back down until we know that all countries can afford this vaccine.”

The pneumococcal conjugate vaccine (PCV) is currently available from only two pharmaceutical corporations: Pfizer and GlaxoSmithKline (GSK).

Pfizer and GSK face criticism by health activists for pricing out their vaccines of reach of many parents, governments and treatment providers, due to a duopoly market and a lack of sufficient competition from developing country vaccine manufacturers.

Approximately, one-third of the world’s countries have not been able to introduce PCV, largely because of high prices. Those who have introduced the vaccine are struggling with its costs. South Africa spends more than 50 percent of its vaccination budget on purchasing PCV13 alone and this is set to continue for another decade unless patent barriers are removed to bring in more competition.
X
Sections
Follow us on
Available On